JP Morgan issued a new TR1 this morning bringing their shareholding to 6.9%, this is of course very positive news that such a large fund is heavily invested in hVIVO and supportive of the business and their story.
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00B9275X97
Issuer Name
hVIVO PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
JPMorgan Asset Management Holdings Inc.
City of registered office (if applicable)
Wilmington
Country of registered office (if applicable)
United States of America
4. Details of the shareholder
|
Name |
City of registered office |
Country of registered office |
|
JPMorgan Asset Management (UK) Limited |
London |
United kingdom |
5. Date on which the threshold was crossed or reached
12-Mar-2024
6. Date on which Issuer notified
13-Mar-2024
7. Total positions of person(s) subject to the notification obligation
|
|
% of voting rights attached to shares (total of 8.A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer |
|
Resulting situation on the date on which threshold was crossed or reached |
5.048410% |
1.868195% |
6.916605% |
47,058,678 |
|
Position of previous notification (if applicable) |
3.215703% |
1.829392% |
5.045095% |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible) |
Number of direct voting rights (DTR5.1) |
Number of indirect voting rights (DTR5.2.1) |
% of direct voting rights (DTR5.1) |
% of indirect voting rights (DTR5.2.1) |
|
GB00B9275X97 |
34,347,989 |
5.048410% |
||
|
Sub Total 8.A |
34,347,989 |
5.048410% |
||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Number of voting rights that may be acquired if the instrument is exercised/converted |
% of voting rights |
|
|
||||
|
Sub Total 8.B1 |
||||
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Physical or cash settlement |
Number of voting rights |
% of voting rights |
|
Cash Settled – Equity Swaps |
N/A |
N/A |
Cash |
12,710,689 |
1.868195% |
|
Sub Total 8.B2 |
12,710,689 |
1.868195% |
|||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
|
Ultimate controlling person |
Name of controlled undertaking |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
JPMorgan Asset Management Holdings Inc. |
JPMorgan Asset Management (UK) Limited |
6.804127% |
||
|
JPMorgan Asset Management Holdings Inc. |
JPMorgan Asset Management (China) Company Limited |
|||
|
JPMorgan Asset Management Holdings Inc. |
JPMorgan Asset Management (Taiwan) Limited |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Chain of controlled undertakings:
JPMorgan Asset Management Holdings Inc
JPMorgan Asset Management International Limited (100%)
JPMorgan Asset Management (UK) Limited (100%)
JPMorgan Asset Management Holdings Inc.
JPMorgan Asset Management (China) Company Limited (100%)
JPMorgan Asset Management Holdings Inc.
JPMorgan Asset Management (Asia) Inc. (100%)
JPMorgan Asset Management (Taiwan) Limited (100%)
12. Date of Completion
13-Mar-2024
13. Place Of Completion
Hyderabad, India
About hVIVO
hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group’s fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.
